Cue Biopharma
CUE
75 hedge funds and large institutions have $32.1M invested in Cue Biopharma in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 25 increasing their positions, 15 reducing their positions, and 13 closing their positions.
145% more call options, than puts
Call options by funds: $240K | Put options by funds: $98K
67% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 15
0.03% less ownership
Funds ownership: 1.07% → 1.04% (-0.03%)
4% less funds holding
Funds holding: 78 → 75 (-3)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
36% less capital invested
Capital invested by funds: $50.5M → $32.1M (-$18.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SMH
Sanders Morris Harris
Houston,
Texas
|
+$943K |
| 2 |
Millennium Management
New York
|
+$443K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$249K |
| 4 |
BlackRock
New York
|
+$205K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$173K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.47M |
| 2 |
Renaissance Technologies
New York
|
-$310K |
| 3 |
CW
Channel Wealth
Santa Barbara,
California
|
-$174K |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
-$157K |
| 5 |
OQS
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
|
-$138K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
76
Silverarc Capital Management
Boston,
Massachusetts
| – | -$1.47M | -13,447 | Closed |
|
|
JF
77
Jump Financial
Chicago,
Illinois
| – | -$157K | -1,430 | Closed |
|
|
OQS
78
Occudo Quantitative Strategies
Fort Lauderdale,
Florida
| – | -$138K | -1,259 | Closed |
|
79
D.E. Shaw & Co
New York
| – | -$134K | -1,223 | Closed |
|
80
Two Sigma Advisers
New York
| – | -$98.9K | -903 | Closed |
|
81
Mirae Asset Global Investments
Seoul,
South Korea
| – | -$76.8K | -701 | Closed |
|
82
Verition Fund Management
Greenwich,
Connecticut
| – | -$76.7K | -700 | Closed |
|
|
MIM
83
MetLife Investment Management
Whippany,
New Jersey
| – | -$67.6K | -617 | Closed |
|
|
GCP
84
GSA Capital Partners
London,
United Kingdom
| – | -$67K | -609 | Closed |
|
|
VF
85
Virtu Financial
New York
| – | -$64K | -586 | Closed |
|
86
Two Sigma Investments
New York
| – | -$51.4K | -469 | Closed |
|
|
AG
87
Algert Global
San Francisco,
California
| – | -$48K | -441 | Closed |
|
|
MLICM
88
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$7K | -64 | Closed |
|
CUE Hedge Fund Activity: Q3 2023 in Review
75 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q3 2023, worth a combined $32.1M — down 36% from $50.5M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CUE and 10 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 25 added.
The largest buyer was Sanders Morris Harris, adding an estimated $943K. The largest seller was Silverarc Capital Management, exiting entirely with an estimated $1.47M sold.
- 75 institutional investors held Cue Biopharma (CUE) as of Q3 2023, down from 78 in Q2 2023.
- Funds reported $32.1M of Cue Biopharma stock for Q3 2023, down 36% quarter-over-quarter.
- 10 funds opened new Cue Biopharma positions in Q3 2023 and 13 closed out, a net change of -3 holders.
- The largest Cue Biopharma buyer in Q3 2023 was Sanders Morris Harris, an estimated $943K added.
- The largest Cue Biopharma seller in Q3 2023 was Silverarc Capital Management, an estimated $1.47M sold.
Based on aggregated 13F filings for Q3 2023.